TITLE

COMPANY SPOTLIGHT - Merck KGaA

PUB. DATE
January 2007
SOURCE
PharmaWatch: Cancer;Jan2007, Vol. 6 Issue 1, p19
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article focuses on the joint venture of German drug maker Merck KGaA and Chinese pharmaceutical company Chi-Med concerning the development of new treatments for cancer in the pharmaceutical industry. The two companies reach into an agreement that Merck will develop new treatments for cancer with traditional Chinese medicines from Chi-Med. Particularly, a small molecule anti-cancer drugs will be developed wherein over 10,000 natural substances from Chi-Med will be drawn.
ACCESSION #
23952497

 

Related Articles

  • COMPANY SPOTLIGHT - Merck KGaA.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p41 

    The article reports on a joint venture between Merck KGaA and Chi-Med, both a pharmaceutical company, in developing treatments for cancer with traditional Chinese medicine. The two companies have agreed to develop small molecule anti-cancer drugs using 10,000 natural substances from Chi-Med to...

  • A Chinese. Beacham, Will // ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p3 

    The article discusses the use of traditional Chinese medicines by big pharmaceutical companies in search of new chemicals for the drugs. As stated big pharmaceutical companies are collaborating with Asian counterparts supplying Chinese medicines to be used by the western laboratories in drug...

  • Drug & Device Pipeline News.  // CenterWatch Weekly;11/16/2015, Vol. 19 Issue 45, p7 

    A chart is presented depicting the trial status of the drug and device pipeline of several global pharmaceutical companies, including Hutchison China MediTech Ltd., Cymabay Therapeutics Inc. and Kite Pharma Inc.

  • Merck KGaA applies for approval of Erbitux in Europe.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p13 

    Announces that Merck KGaA has applied for approval of Erbitux in Europe indicated for metastatic colorectal cancer. Approval sought for the drug as a monotherapy and in combination with the standard chemotherapy irinotecan.

  • Merck KGaA to Close Sites, Outsource New Biopharma Drugs. Alperowicz, Natasha // Chemical Week;11/6/2002, Vol. 164 Issue 44, p35 

    Presents updates on the plans of Merck KGaA company for its operations as of November 6, 2002. Information on its plan to rationalize its drugs manufacturing operations; Details of its plans to increase its overall ethical pharmaceutical sales; Plans for its generics business.

  • Merck KGaA applies for approval of Erbitux in Europe.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p16 

    Reports that Merck KGaA has filed marketing authorization applications with the European Agency for the approval of the drug, Erbitux. Indications for the Erbitux drugs; Presentation of the clinical study of the drug; Evaluation of the company's products.

  • Decisions Update.  // PharmaWatch: Biotechnology;May2006, Vol. 5 Issue 5, p14 

    The article offers news briefs in the pharmaceutical industry worldwide in 2006. Merck KgaA's anticancer drug Erbitux has been approved to be used in the expanded indication of head and neck cancer by the regulators of the European Commission. The U.S. Food and Drugs Administration has granted...

  • Merck to Move Forward With Oncothyreon Cancer Vaccine. Shaffer, Catherine // BioWorld Today;9/26/2013, Vol. 24 Issue 185, p1 

    The article reports that the chemical and pharmaceutical company Merck KGaA will continue development of tecemotide cancer vaccine following the 2012 Phase III trial which failed to meet its primary endpoint of improving overall survival. It will launch the Phase III trial in patients with...

  • Cancer News Round-up.  // PharmaWatch: Cancer;May2010, Vol. 9 Issue 5, p2 

    The article offers cancer drug developments in several pharmaceutical companies. It announces the temporary suspension of the clinical program for Stimuvax in all recruiting studies by Merck KgaA and the final results for the Phase III trial between Abraxine with Taxol by Abraxis BioScience Inc....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics